334 related articles for article (PubMed ID: 33254439)
21. Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy.
Zhang M; Zou Y; Zhou X; Zhou J
Front Immunol; 2022; 13():954129. PubMed ID: 36172373
[TBL] [Abstract][Full Text] [Related]
22. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
23. Targeting STING with covalent small-molecule inhibitors.
Haag SM; Gulen MF; Reymond L; Gibelin A; Abrami L; Decout A; Heymann M; van der Goot FG; Turcatti G; Behrendt R; Ablasser A
Nature; 2018 Jul; 559(7713):269-273. PubMed ID: 29973723
[TBL] [Abstract][Full Text] [Related]
24. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.
Khoo LT; Chen LY
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30446584
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy.
Berger G; Marloye M; Lawler SE
Trends Mol Med; 2019 May; 25(5):412-427. PubMed ID: 30885429
[TBL] [Abstract][Full Text] [Related]
26. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
27. Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application.
Pu F; Chen F; Liu J; Zhang Z; Shao Z
Onco Targets Ther; 2021; 14():1501-1516. PubMed ID: 33688199
[TBL] [Abstract][Full Text] [Related]
28. The cGAS-STING Pathway: A Promising Immunotherapy Target.
Ou L; Zhang A; Cheng Y; Chen Y
Front Immunol; 2021; 12():795048. PubMed ID: 34956229
[TBL] [Abstract][Full Text] [Related]
29. An updated patent review of stimulator of interferon genes agonists (2021 - present).
Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
33. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM; Sheehy TL; Wilson JT
Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
[TBL] [Abstract][Full Text] [Related]
34. Unlocking the promise of systemic STING agonist for cancer immunotherapy.
Sun X; Zhou X; Lei YL; Moon JJ
J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564
[TBL] [Abstract][Full Text] [Related]
35. STING pathway agonism as a cancer therapeutic.
Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
[TBL] [Abstract][Full Text] [Related]
36. The triggers of the cGAS-STING pathway and the connection with inflammatory and autoimmune diseases.
Zhou R; Xie X; Li X; Qin Z; Wei C; Liu J; Luo Y
Infect Genet Evol; 2020 Jan; 77():104094. PubMed ID: 31689545
[TBL] [Abstract][Full Text] [Related]
37. The cGAS-STING pathway: more than fighting against viruses and cancer.
Bao T; Liu J; Leng J; Cai L
Cell Biosci; 2021 Dec; 11(1):209. PubMed ID: 34906241
[TBL] [Abstract][Full Text] [Related]
38. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
39. Cocktail strategy based on a dual function nanoparticle and immune activator for effective tumor suppressive.
Li Q; Chen Q; Yang X; Zhang Y; Lv L; Zhang Z; Zeng S; Lv J; Liu S; Fu B
J Nanobiotechnology; 2022 Feb; 20(1):84. PubMed ID: 35177088
[TBL] [Abstract][Full Text] [Related]
40. An RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway.
Bose D; Su Y; Marcus A; Raulet DH; Hammond MC
Cell Chem Biol; 2016 Dec; 23(12):1539-1549. PubMed ID: 27889408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
